MedTrace Logo

Safety and Efficacy of PSMA-Targeted Fluorescent Contrast Agent DGPR1008 for Intraoperative Imaging in Robot-Assisted Radical Prostatectomy

NCT07415135 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-02-17

No results posted yet for this study

Summary

This study is a single-center, single-arm, open-label exploratory study to evaluate the safety and efficacy of fluorescent imaging combined with a robotic surgical control system for robot-assisted radical prostatectomy.

Conditions

Interventions

DRUG

0.02 mg/kg of DGPR1008 Injection was administered 24 hours before surgery

0.02 mg/kg

DRUG

0.04 mg/kg of DGPR1008 Injection was administered 24 hours before surgery

0.04 mg/kg

DRUG

0.06 mg/kg of DGPR1008 Injection was administered 24 hours before surgery

0.06 mg/kg

Sponsors & Collaborators

  • Zhu Yinjie

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2026-06-30
Completion
2026-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07415135 on ClinicalTrials.gov